Cargando…

Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl

OBJECTIVE: Lung cancer is the leading cause of non-AIDS-defining cancer deaths among HIV-infected individuals. Although lung cancer screening with low-dose computed tomography (LDCT) is endorsed by multiple national organizations, whether HIV-infected individuals would have similar benefit as uninfe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Chung Yin, Sigel, Keith, Criss, Steven D., Sheehan, Deirdre F., Triplette, Matthew, Silverberg, Michael J., Henschke, Claudia I., Justice, Amy, Braithwaite, R. Scott, Wisnivesky, Juan, Crothers, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991188/
https://www.ncbi.nlm.nih.gov/pubmed/29683843
http://dx.doi.org/10.1097/QAD.0000000000001818
Descripción
Sumario:OBJECTIVE: Lung cancer is the leading cause of non-AIDS-defining cancer deaths among HIV-infected individuals. Although lung cancer screening with low-dose computed tomography (LDCT) is endorsed by multiple national organizations, whether HIV-infected individuals would have similar benefit as uninfected individuals from lung cancer screening is unknown. Our objective was to determine the benefits and harms of lung cancer screening among HIV-infected individuals. DESIGN: We modified an existing simulation model, the Lung Cancer Policy Model, for HIV-infected patients. DATA SOURCES: Veterans Aging Cohort Study, Kaiser Permanente Northern California HIV Cohort, and medical literature. TARGET POPULATION: : HIV-infected current and former smokers. TIME HORIZON: : Lifetime. PERSPECTIVE: : Population. INTERVENTION: Annual LDCT screening from ages 45, 50, or 55 until ages 72 or 77 years. MAIN OUTCOME MEASURES: Benefits assessed included lung cancer mortality reduction and life-years gained; harms assessed included numbers of LDCT examinations, false-positive results, and overdiagnosed cases. RESULTS OF BASE-CASE ANALYSIS: For HIV-infected patients with CD4(+) cell count at least 500 cells/μl and 100% antiretroviral therapy adherence, screening using the Centers for Medicare & Medicaid Services criteria (age 55–77, 30 pack-years of smoking, current smoker or quit within 15 years of screening) would reduce lung cancer mortality by 18.9%, similar to the mortality reduction of uninfected individuals. Alternative screening strategies utilizing lower screening age and/or pack-years criteria increase mortality reduction, but require more LDCT examinations. LIMITATIONS: Strategies assumed 100% screening adherence. CONCLUSION: Lung cancer screening reduces mortality in HIV-infected patients with CD4(+) cell count at least 500 cells/μl, with a number of efficient strategies for eligibility, including the current Centers for Medicare & Medicaid Services criteria.